Circulating endothelial cells as biomarkers in clinical oncology

Research output: Contribution to journalArticlepeer-review


Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a "catalytic" role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalMicrovascular Research
Issue number3
Publication statusPublished - May 2010


  • Angiogenesis
  • Endothelial cells
  • Endothelial progenitors

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Circulating endothelial cells as biomarkers in clinical oncology'. Together they form a unique fingerprint.

Cite this